EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Serum Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Differential Biomarkers of Response to Dimethyl Fumarate and Ocrelizumab in Multiple Sclerosis

Alessandra Mingione iD, Andrea Corona, Corinne Monzani, Alen Zollo iD, Carola Cirocco, Tiziana Zaccone iD, Mariangela Scavone iD, Gian Marco Podda, Paola Signorelli iD, Monica Miozzo, Alberto Priori iD, Filippo Martinelli-Boneschi iD

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27031441 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Alessandra Mingione und 11 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Precision Medicine of Neurological Diseases, Department of Health Science, University of Milan, 20142 Milan, Italy. Hauptthemen laut MEDLINE: Dimethyl Fumarate, Neurofilament Proteins, Glial Fibrillary Acidic Protein, Multiple Sclerosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union-NextGenerationEU., European Union—NextGenerationEU.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease. Quantifying neuronal damage is a critical step for patient care. Neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) are the most promising serum biomarkers reflecting neuronal damage and astroglial activation, respectively. This study analyzed sNfL and sGFAP in 177 MS patients and 71 healthy controls (HCs) using SIMOA technology, classifying patients as responders (Rs) or non-responders (NRs) based on “No Evidence of Disease Activity 3” (NEDA-3) status during two years of treatment. Longitudinal analyses were performed for Dimethyl fumarate (DMF) and Ocrelizumab (OCRE) treatment. Biomarker–age correlation analysis in HCs confirmed correlation between both NfL and GFAP, with age and cut-off values specific for age decades being calculated. Both biomarkers were higher in MS patients compared to HCs. sNfL showed a significant increase in NR patients overall. In contrast, sGFAP was elevated in the low-to-moderate-efficacy treatment agents (LETAs) NR group and also in the DMF NR subgroup, suggesting that it monitors persistent astrogliosis. Longitudinal analysis showed that both biomarkers decreased during DMF treatment after one year. During OCRE treatment, sNfL rapidly reduced to HC levels within one year, while sGFAP decreased only after two years. This highlights that OCRE acts differently on the pathological processes linked to the two biomarkers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dimethyl FumarateNeurofilament ProteinsGlial Fibrillary Acidic ProteinMultiple SclerosisAntibodies, Monoclonal, HumanizedHumansFemaleBiomarkersAdultMaleMiddle Aged

Stichwörter der Autor:innen

Dimethyl fumarateOcrelizumabSIMOAmultiple sclerosissGFAPsNfL

Substanzen

Dimethyl FumarateNeurofilament ProteinsGlial Fibrillary Acidic ProteinBiomarkersneurofilament protein LAntibodies, Monoclonal, HumanizedGFAP protein, human

Autor:innen und Institutionen

  • Laboratory of Precision Medicine of Neurological Diseases, Department of Health Science, University of Milan, 20142 Milan, Italy.
  • Aldo Ravelli Center for Neurotechnology and Experimental Brain Therapeutics, Department of Health Sciences, Università degli Studi di Milano, 20142 Milan, Italy.
  • Clinical Neurology Unit, ASST Santi Paolo e Carlo, 20142 Milan, Italy.
  • Laboratory of Haemostasis and Thrombosis, Dipartimento di Scienze della Salute, Università degli Studi di Milano, 20142 Milan, Italy.
  • Division of Medicina Generale SP, ASST Santi Paolo e Carlo, 20142 Milan, Italy.
  • Biochemistry Laboratory, IRCCS Policlinico San Donato, 20097 Milan, Italy.

ORCID-Profile: Alessandra Mingione, Alen Zollo, Tiziana Zaccone, Mariangela Scavone, Paola Signorelli, Alberto Priori, Filippo Martinelli-Boneschi

Förderung

  • European Union-NextGenerationEU.
  • European Union—NextGenerationEU

Zitieren

APA

Mingione, A., Corona, A., Monzani, C., Zollo, A., Cirocco, C., Zaccone, T., Scavone, M., Podda, G. M., Signorelli, P., Miozzo, M., Priori, A., & Martinelli-Boneschi, F. (2026). Serum Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Differential Biomarkers of Response to Dimethyl Fumarate and Ocrelizumab in Multiple Sclerosis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27031441

Vancouver

Mingione A, Corona A, Monzani C, Zollo A, Cirocco C, Zaccone T, et al. Serum Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Differential Biomarkers of Response to Dimethyl Fumarate and Ocrelizumab in Multiple Sclerosis. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27031441

BibTeX
@article{Mingione2026,
  author = {Mingione, Alessandra and Corona, Andrea and Monzani, Corinne and Zollo, Alen and Cirocco, Carola and Zaccone, Tiziana and Scavone, Mariangela and Podda, Gian Marco and Signorelli, Paola and Miozzo, Monica and Priori, Alberto and Martinelli-Boneschi, Filippo},
  title = {Serum Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Differential Biomarkers of Response to Dimethyl Fumarate and Ocrelizumab in Multiple Sclerosis},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27031441}
}
Kostenlos starten →